Posted by Michael Wonder on 23 Sep 2019
Two more bills aiming to boost biosimilars introduced in Congress
23 September 2019 - Two biosimilar bills, both with bipartisan sponsors, were unveiled last week and aim to boost uptake in the United States, one through increased Medicare Part payment and the other via additional education.
Two biosimilar bills, both with bipartisan sponsors, were unveiled last week and aim to boost uptake in the United States, one through increased Medicare Part payment and the other via additional education.
Payment for biosimilars in Medicare Part B would get a temporary boost through the Bolstering Innovative Options to Save Immediately on Medicines Act (BIOSIM), which would temporarily increase reimbursement for biosimilar drugs to 8% of the average sales price (ASP), up from the current 6% of the ASP. The larger payments would last for 5 years in an effort to help increase their utilization by doctors administering the drugs.
